Other studies suggest that using bispecific antibodies in combination with other cancer therapies can be more effective in treating cancer and reduce the risk of resistance as it is designed to detect EGFR and EPHA2 proteins, which are located on the cancer cells’ surface [125, 126]. Here, EPHA2 is linked to cancer.